



catalyst, the reactions took almost exclusively the latter path.



Ar = 4-ClC₆H₄ (**b**), 4-NO₂C₆H₄ (**c**)

The rapid disappearance of amines from the reaction mixture at the initial stage of cyclization accompanied by the simultaneous formation of **4b,c** suggests that the reactions with sulfonylguanidines involve compounds **4b,c**, which are products of condensation of amines with formaldehyde.

Using the synthesis of compound **3e** as an example, it was demonstrated that cyclization of sulfonylguanidines with **4b,c** (procedure C) afforded products in somewhat higher yields compared to those obtained according to the conventional scheme (59.1 and 54.7%, respectively). In addition, this reaction is a convenient synthetic procedure, which allows one to do away with gaseous and low-boiling amines as the starting reagents.



It should be noted that it is necessary to add one mole of CH_2O to maintain the stoichiometric reagent ratio; otherwise the reaction mixture would contain a

large amount of $\text{R}'\text{NH}_2$ resulting in a decrease in the yield of compounds **3** upon crystallization



The synthesized hexahydrotriazines **3** are high-melting crystalline compounds. Their melting is accompanied by decomposition. The structures of these compounds were confirmed by ^1H NMR spectroscopy.

Therefore, condensation of sulfonylguanidines with primary alkyl(aryl)amines is a convenient procedure for the synthesis of the previously unknown 5-substituted 2-alkyl(aryl)sulfonyliminohexahydro-1,3,5-triazines.

Experimental

The ^1H NMR spectra were recorded on Bruker WM-250 (250 MHz) and Bruker AM-300 (300 MHz) instruments. The ^1H NMR chemical shifts are given relative to the signal of the solvent (DMSO- d_6 , 2.50 ppm). The melting points were determined on a Boetius stage. The course of the reactions and the purities of the products were monitored by TLC on Silufol UV-250 plates (a 1 : 2 : 7 MeOH—C₆H₆—Et₂O system as the eluent).

Amines **2c,h,g,i** were purchased from Lancaster. The remaining amines and zinc chloride are commercial reagents (high purity or analytical grade) produced in Russia. Sulfonylguanidines **1a,c,d** were synthesized according to known procedures.^{2,3} 1,3,5-Trimethyl- (**4a**) and 1,3,5-tribenzylhexahydro-1,3,5-triazines (**4d**) were prepared according to procedures reported previously.^{4,5}





The characteristics of the resulting compounds are identical with those published in the literature. All reagents and solvents were used without additional purification or dryness, unless otherwise indicated.

2-(4-Methyl-3-nitrophenyl)sulfonylguanidine (1b). Compound **1a** (0.5 g, 2.35 mmol) was added portionwise to a mixture of concentrated H_2SO_4 (2.5 mL) and HNO_3 (d 1.47; 5 mL) cooled in an ice bath. The reaction mixture was stirred at 5°C for 1 h and then poured onto crushed ice (20 g). The precipitate that formed was filtered off, washed several times with ice water, and dried in air. After crystallization of the residue (0.54 g), compound **1b** was obtained in a yield of 0.44 g (72.6%), m.p. $228\text{--}230^\circ\text{C}$ (96% EtOH). Found (%): C, 37.42; H, 3.88; S, 12.35. C₈H₁₀N₄O₄S₁. Calculated: C, 37.21; H, 3.90; S, 12.42. ^1H NMR, δ : 2.57 (s, 3 H, Me); 6.78 (br.s, 4 H, NH₂); 7.66 (d, 1 H, Ar, $J = 8.0$ Hz); 7.96 (d, 1 H, Ar, $J = 8.0$ Hz); 8.27 (s, 1 H, Ar). Compound **1b** was prepared analogously to **1a** in 37.1% yield.

2-Butylsulfonylguanidine (1e) was prepared according to a procedure reported previously² analogously to compound **1a** in 70.3% yield, m.p. $163\text{--}165^\circ\text{C}$ (EtOH) (*cf.* lit. data:⁶ $158\text{--}159^\circ\text{C}$). ^1H NMR, δ : 0.87 (t, 3 H, Me, $J = 7.3$ Hz); 1.28–1.45 and 1.53–1.68 (both m, 2 H each, CH₂); 2.83 (t, 2 H, CH₂SO₂, $J = 7.9$ Hz); 6.57 (br.s, 4 H, NH₂).

Preparation of 5-substituted 2-alkyl(aryl)sulfonyliminohexahydro-1,3,5-triazines (3). **Procedure A.** A mixture of alkyl(aryl)sulfonylguanidine **1a–e** (10 mmol), $(\text{CH}_2\text{O})_n$ (24 mmol), amine **2b–k** (10 mmol), and $\text{TsOH} \cdot \text{H}_2\text{O}$ (0.1 g; in the case of condensation of arylsulfonylguanidines with arylamines, the amount of the catalyst was increased to 0.2 g) was thoroughly ground in a mortar, transferred into a wide tube, which was placed into a boiling bath, and heated for 1–4 h until an aqueous condensate ceased to form at the tube edges (TLC control was additionally performed). The sintered mixture was triturated with Et₂O (10–20 mL), transferred to a porous filter, and washed successively with Et₂O (10 mL) and Me₂CO

Table 1. Procedures for the preparation of compounds **3a–s** and their characteristics

Compound	R	R ¹	Procedure for the preparation	Yield* (%)	M.p./°C (solvent)	Found _____ Calculated (%)					Molecular formula
						C	H	Cl	N	S	
3a	<i>p</i> -Tol	Me	C	<u>74.5</u> 58.7	203–205 (50% EtOH)	<u>49.31</u> 49.24	<u>5.94</u> 6.01		<u>21.06</u> 20.88	<u>11.74</u> 11.95	C ₁₁ H ₁₆ N ₄ O ₂ S
3b	<i>p</i> -Tol	All	A	<u>91.2</u> 72.1	178–180 (50% EtOH)	<u>53.21</u> 53.04	<u>6.08</u> 6.16		<u>18.80</u> 19.03	<u>10.71</u> 10.89	C ₁₃ H ₁₈ N ₄ O ₂ S
3c	<i>p</i> -Tol	CH ₂ CH ₂ OH	A	<u>58.7</u> 40.1	169–171 (96% EtOH)	<u>48.23</u> 48.31	<u>6.18</u> 6.08		<u>18.63</u> 18.78	<u>10.65</u> 10.75	C ₁₂ H ₁₈ N ₄ O ₃ S
3d	<i>p</i> -Tol	CH ₂ COONa	A	<u>95.8</u> 65.9	209–212 (50% EtOH)	<u>42.95</u> 43.11	<u>4.55</u> 4.52		<u>16.63</u> 16.76	<u>9.71</u> 9.59	C ₁₂ H ₁₅ N ₄ NaO ₄ S
3e	<i>p</i> -Tol	Bn	A	<u>64.5</u> 54.7	200–202	<u>59.35</u> 59.28	<u>6.10</u> 5.85		<u>16.22</u> 16.27	<u>9.28</u> 9.31	C ₁₇ H ₂₀ N ₄ O ₂ S
			C	<u>69.8</u> 59.1	(50% EtOH)						
3f	<i>p</i> -Tol		A	<u>88.9</u> 57.5	203–205 (96% EtOH)	<u>61.66</u> 61.80	<u>6.60</u> 6.84		<u>16.48</u> 16.38	<u>7.43</u> 7.50	C ₂₂ H ₂₉ N ₅ O ₂ S
3g	<i>p</i> -Tol	4-ClC ₆ H ₄	A	<u>44.0</u> 24.2	273–275	<u>52.79</u> 52.67	<u>4.89</u> 4.70	<u>9.74</u> 9.72	<u>15.54</u> 15.36	<u>8.81</u> 8.79	C ₁₆ H ₁₇ Cl ₁ N ₄ O ₂ S
			B	<u>60.3</u> 40.2	(DMSO)						
3h	<i>p</i> -Tol	3-NO ₂ C ₆ H ₄	A	<u>79.8</u> 43.7	264–266	<u>50.99</u> 51.19	<u>4.55</u> 4.56		<u>18.70</u> 18.66	<u>8.44</u> 8.54	C ₁₆ H ₁₇ N ₅ O ₄ S
			B	<u>82.9</u> 50.0	(DMSO)						
3i	4-Me-3-NO ₂ C ₆ H ₃	Me	C	<u>39.2</u> 21.6	211–213 (50% EtOH)	<u>42.16</u> 42.17	<u>5.05</u> 4.83		<u>22.50</u> 22.35	<u>10.22</u> 10.23	C ₁₁ H ₁₅ N ₅ O ₄ S
3j	4-Me-3-NO ₂ C ₆ H ₃	4-ClC ₆ H ₄	A	<u>42.7</u> 28.5	245–247 (DMSO)	<u>46.79</u> 46.89	<u>4.03</u> 3.94	<u>8.74</u> 8.65	<u>17.15</u> 17.09	<u>7.91</u> 7.82	C ₁₆ H ₁₆ Cl ₁ N ₅ O ₄ S
3k	4-AcNHC ₆ H ₄	All	A	<u>81.5</u> 65.2	200–202 (96% EtOH)	<u>49.89</u> 49.84	<u>5.66</u> 5.68		<u>20.98</u> 20.76	<u>9.32</u> 9.50	C ₁₄ H ₁₉ N ₅ O ₂ S
3l	4-AcNHC ₆ H ₄	<i>cyclo</i> -C ₆ H ₁₁	A	<u>84.0</u> 61.6	225–227 (50% EtOH)	<u>53.85</u> 53.81	<u>6.64</u> 6.64		<u>18.14</u> 18.46	<u>8.36</u> 8.45	C ₁₇ H ₂₅ N ₅ O ₃ S
3m	4-AcNHC ₆ H ₄		A	<u>93.5</u> 56.1	201–203 (96% EtOH)	<u>58.79</u> 58.70	<u>6.39</u> 6.43		<u>17.74</u> 17.86	<u>6.93</u> 6.81	C ₂₃ H ₃₀ N ₆ O ₃ S ₁
3n	4-AcNHC ₆ H ₄	4-ClC ₆ H ₄	A	<u>39.2</u> 20.6	278–280	<u>50.08</u> 50.06	<u>4.67</u> 4.45	<u>8.62</u> 8.69	<u>17.43</u> 17.17	<u>7.79</u> 7.86	C ₁₇ H ₁₈ Cl ₁ N ₅ O ₃ S ₁
			B	<u>45.1</u> 29.6	(DMSO)						
3o	4-AcNHC ₆ H ₄	4-NO ₂ C ₆ H ₄	A	<u>38.2</u> 20.0	285–287	<u>48.91</u> 48.80	<u>4.39</u> 4.34		<u>20.01</u> 20.08	<u>7.66</u> 7.66	C ₁₇ H ₁₈ N ₆ O ₅ S ₁
			B	<u>79.3</u> 47.8	(DMSO)						
3p	4-NO ₂ C ₆ H ₄	Me	C	<u>33.4</u> 13.4	191–193 (50% EtOH)	<u>40.12</u> 40.13	<u>4.48</u> 4.38		<u>23.61</u> 23.40	<u>10.63</u> 10.71	C ₁₀ H ₁₃ N ₅ O ₄ S ₁
3q	Bu		A	<u>61.0</u> 31.1	198–200 (50% EtOH)	<u>47.99</u> 47.98	<u>6.66</u> 6.71		<u>18.37</u> 18.65	<u>10.71</u> 10.67	C ₁₂ H ₂₀ N ₄ O ₃ S ₁
3r	Bu		A	<u>86.1</u> 51.8	219–221 (96% EtOH)	<u>58.19</u> 57.99	<u>7.98</u> 7.94		<u>17.83</u> 17.80	<u>8.20</u> 8.15	C ₁₉ H ₃₁ N ₅ O ₂ S ₁
3s	Bu	4-ClC ₆ H ₄	A	<u>65.0</u> 51.1	238–240 (96% EtOH)	<u>47.23</u> 47.20	<u>5.88</u> 5.79	<u>10.38</u> 10.72	<u>16.71</u> 16.94	<u>9.39</u> 9.69	C ₁₃ H ₁₉ Cl ₁ N ₄ O ₂

* The ratio between the raw product and the product obtained after recrystallization.

(2–3 times, 20 mL). The raw product was dried in air and recrystallized from the corresponding solvent (see Table 1) to obtain compounds **3b–h**; **j–o**, and **p–s**.

Procedure B. A mixture of arylsulfonylguanidine **1a,c** (10 mmol), (CH₂O)_n (24 mmol), arylamine **2i–k** (10 mmol),

and TsOH·H₂O (0.2 g) in anhydrous MeCN (100 mL; prepared by distillation over P₂O₅) was refluxed for 1–2 h. Then the solvent was slowly distilled off under atmospheric pressure to ~1/3 of the initial volume. The resulting suspension was cooled to ~20 °C. The precipitate was filtered off, washed with

MeCN, and dried in air. Compounds **3g,h,n,o** were obtained after crystallization from the corresponding solvent (see Table 1).

Procedure C. A mixture of arylsulfonylguanidine **1a,b,d** (10 mmol), $(\text{CH}_2\text{O})_n$ (12 mmol), and $\text{TsOH} \cdot \text{H}_2\text{O}$ (0.1 g) or ZnCl_2 (0.1 g) was thoroughly ground in a mortar and transferred into a wide tube. Then a solution of trihexahydro-1,3,5-triazine (**4a,b**) (3.3 mmol) in Et_2O (1–2 mL) was added to the reaction mixture. After removal of Et_2O on a warm water bath, the tube was transferred into a boiling water bath. Subsequent operations were carried out as described in procedure A.

Compounds **3a,e,i,p** were obtained.

The physicochemical and spectral characteristics of the corresponding hexahydrotriazines **3** prepared according to different procedures are identical.

5-Methyl-2-*p*-tosyliminohexahydro-1,3,5-triazine (3a).

$^1\text{H NMR}$, δ : 2.28 (s, 3 H, MeN); 2.34 (s, 3 H, MeAr); 4.03 (s, 4 H, NCH_2N); 7.28 and 7.67 (both d, 2 H each, Ar, $J = 8.0$ Hz); 7.55 (br.s, 2 H, NH).

5-Allyl-2-*p*-tosyliminohexahydro-1,3,5-triazine (3b).

$^1\text{H NMR}$, δ : 2.34 (s, 3 H, Me); 3.03 (d, 2 H, $\text{CH}_2\text{—CH=CH}_2$, $J = 4.8$ Hz); 4.08 (s, 4 H, NCH_2N); 5.00–5.18 (m, 2 H, CH=CH_2); 5.65–5.88 (m, 1 H, CH); 7.28 and 7.69 (both d, 2 H each, Ar, $J = 8.1$ Hz); 7.57 (br.s, 2 H, NH).

5-(2-Hydroxyethyl)-2-*p*-tosyliminohexahydro-1,3,5-triazine (3c).

$^1\text{H NMR}$, δ : 2.34 (s, 3 H, Me); 2.53 (t, 2 H, NCH_2CH_2 , $J = 4.7$ Hz); 3.48 (br.t, 2 H, $\text{CH}_2\text{CH}_2\text{O}$, $J = 4.7$ Hz); 4.12 (s, 4 H, NCH_2N); 4.55 (br.s, 1 H, OH); 7.28 and 7.67 (both d, 2 H each, Ar, $J = 8.0$ Hz); 7.58 (br.s, 2 H, NH).

Sodium (2-*p*-tosyliminohexahydro-1,3,5-triazin-5-yl)acetate (3d).

$^1\text{H NMR}$, δ : 2.34 (s, 3 H, Me); 3.00 (s, 2 H, CH_2CO); 4.07 (s, 4 H, NCH_2N); 7.28 and 7.67 (both d, 2 H each, Ar, $J = 8.0$ Hz); 7.75 (br.s, 2 H, NH).

5-Benzyl-2-*p*-tosyliminohexahydro-1,3,5-triazine (3e).

$^1\text{H NMR}$, δ : 2.36 (s, 3 H, Me); 3.56 (s, 2 H, CH_2Ph); 4.08 (s, 4 H, NCH_2N); 7.34–7.48 (m, 5 H, Ph); 7.28 and 7.71 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Me}$, $J = 8.2$ Hz); 7.63 (br.s, 2 H, NH).

5-[1-Benzylpiperidin-1-yl]-2-*p*-tosyliminohexahydro-1,3,5-triazine (3f). $^1\text{H NMR}$, δ : 1.20–1.42, 1.59–1.84, and 2.15–2.30 (all m, 7 H, 3 CH_2 , CH of piperidine); 2.37 (s, 3 H, Me); 2.67–2.81 (m, 2 H, CH_2 of piperidine); 3.39 (s, 2 H, CH_2Ph); 4.18 (s, 4 H, NCH_2N); 7.21 and 7.65 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Me}$, $J = 8.1$ Hz); 7.22–7.32 (m, 5 H, Ph); 7.58 (br.s, 2 H, NH).

5-(4-Chlorophenyl)-2-*p*-tosyliminohexahydro-1,3,5-triazine (3g).

$^1\text{H NMR}$, δ : 2.36 (s, 3 H, Me); 4.72 (s, 4 H, CH_2N); 7.07 and 7.25 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Cl}$, $J = 8.9$ Hz); 7.20 and 7.55 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Me}$, $J = 8.1$ Hz); 7.86 (br.s, 2 H, NH).

5-(3-Nitrophenyl)-2-*p*-tosyliminohexahydro-1,3,5-triazine (3h).

$^1\text{H NMR}$, δ : 2.30 (s, 3 H, Me); 4.87 (s, 4 H, NCH_2N); 7.12 (d, 2 H, $\text{C}_6\text{H}_4\text{Me}$, $J = 8.1$ Hz); 7.47–7.61 and 7.74–7.91 (both m, 6 H, H arom.); 7.96 (br.s, 2 H, NH).

5-Methyl-2-(4-methyl-3-nitrophenylsulfonyl)iminohexahydro-1,3,5-triazine (3i). $^1\text{H NMR}$, δ : 2.29 (s, 3 H, MeN); 2.57 (s, 3 H, Me); 4.05 (s, 4 H, NCH_2N); 7.65 (d, 1 H, Ar, $J = 8.3$ Hz); 7.69 (br.s, 2 H, NH); 7.98 (d, 1 H, Ar, $J = 8.3$ Hz); 8.30 (s, 1 H, Ar).

5-(4-Chlorophenyl)-2-(4-methyl-3-nitrophenylsulfonyl)iminohexahydro-1,3,5-triazine (3j). $^1\text{H NMR}$, δ : 2.58 (s, 3 H, Me); 4.75 (s, 4 H, NCH_2N); 7.01 and 7.19 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Cl}$, $J = 8.5$ Hz); 7.54 (d, 1 H, $\text{C}_6\text{H}_3\text{Me}$, $J = 8.3$ Hz); 7.84 (d, 1 H, $\text{C}_6\text{H}_3\text{Me}$, $J = 8.3$ Hz); 7.97 (s, 2 H, NH); 8.24 (s, 1 H, $\text{C}_6\text{H}_3\text{Me}$).

2-(4-Acetamidophenylsulfonyl)-5-allyliminohexahydro-1,3,5-triazine (3k). $^1\text{H NMR}$, δ : 2.07 (s, 3 H, Me); 3.03 (d, 2 H, $\text{CH}_2\text{CH=CH}_2$, $J = 4.8$ Hz); 4.09 (s, 4 H, NCH_2N); 5.02–5.20 (m, 2 H, CH=CH_2); 5.65–5.88 (m, 1 H, CH=CH_2); 7.57 (br.s, 2 H, NH of the ring); 7.69 (s, 4 H, Ar); 10.21 (s, 1 H, CONH).

2-(4-Acetamidophenylsulfonyl)imino-5-cyclohexylhexahydro-1,3,5-triazine (3l). $^1\text{H NMR}$, δ : 0.87–1.17 and 1.41–1.81 (both m, 10 H, CH_2 of cyclohexane); 2.07 (s, 3 H, Me); 2.15–2.27 (m, 1 H, CH of cyclohexane); 4.19 (s, 4 H, NCH_2N); 7.51 (br.s, 2 H, NH of the ring); 7.69 (s, 4 H, Ar); 10.20 (s, 1 H, CONH).

2-(4-Acetamidophenylsulfonyl)imino-5-(1-benzylpiperidin-4-yl)hexahydro-1,3,5-triazine (3m). $^1\text{H NMR}$, δ : 1.19–1.40 and 1.58–1.85 (both m, 6 H, CH_2 of piperidine); 2.07 (s, 3 H, Me); 2.10–2.30 (m, 1 H, CH of piperidine); 2.64–2.84 (m, 2 H, CH_2 of piperidine); 3.38 (s, 2 H, CH_2Ph); 4.18 (s, 4 H, NCH_2N); 7.15–7.35 (m, 5 H, Ph); 7.50 (br.s, 2 H, NH of the ring); 7.65 (s, 4 H, $\text{C}_6\text{H}_4\text{SO}_2$); 10.10 (s, 1 H, CONH).

2-(4-Acetamidophenylsulfonyl)imino-5-(4-chlorophenyl)hexahydro-1,3,5-triazine (3n). $^1\text{H NMR}$, δ : 2.09 (s, 3 H, Me); 4.71 (s, 4 H, NCH_2N); 7.03 and 7.22 (both d, 2 H each, $\text{C}_6\text{H}_4\text{Cl}$, $J = 8.7$ Hz); 7.63 (s, 4 H, $\text{C}_6\text{H}_4\text{SO}_2$); 7.80 (br.s, 2 H, NH of the ring); 10.18 (s, 1 H, CONH).

2-(4-Acetamidophenylsulfonyl)imino-5-(4-nitrophenyl)hexahydro-1,3,5-triazine (3o). $^1\text{H NMR}$, δ : 2.08 (s, 3 H, Me); 4.89 (s, 4 H, NCH_2N); 7.20 and 8.08 (both d, 2 H each, $\text{C}_6\text{H}_4\text{NO}_2$, $J = 9.1$ Hz); 7.59 (s, 4 H, $\text{C}_6\text{H}_4\text{SO}_2$); 7.89 (br.s, 2 H, NH of the ring); 10.03 (s, 1 H, CONH).

5-Methyl-2-(4-nitrophenylsulfonyl)iminohexahydro-1,3,5-triazine (3p). $^1\text{H NMR}$, δ : 2.38 (s, 3 H, Me); 4.05 (s, 4 H, NCH_2N); 7.75 (br.s, 2 H, NH); 8.05 and 8.35 (both d, 2 H each, Ar, $J = 8.8$ Hz).

2-Butylsulfonylimino-5-[(2-furyl)methyl]hexahydro-1,3,5-triazine (3q). $^1\text{H NMR}$, δ : 0.88 (t, 3 H, Me; $J = 7.0$ Hz); 1.30–1.73 (m, 4 H, CH_2 of the chain); 2.85 (t, 2 H, CH_2 of the chain, $J = 7.7$ Hz); 3.77 (s, 2 H, CH_2Het); 4.13 (s, 4 H, NCH_2N); 6.34 (d, 1 H, Het, $J = 8.6$ Hz); 6.40–6.46 (m, 1 H, Het); 7.49 (br.s, 2 H, NH); 7.61 (s, 1 H, Het).

5-(1-Benzylpiperidin-4-yl)-2-butylsulfonyliminohexahydro-1,3,5-triazine (3r). $^1\text{H NMR}$, δ : 0.92 (t, 3 H, Me, $J = 7.2$ Hz); 1.30–2.06 (m, 10 H, 2 CH_2 of the chain, 3 CH_2 of piperidine); 2.55–2.92 (m, 5 H, CH_2 of the chain, CH_2 , CH of piperidine); 3.43 (s, 2 H, CH_2Ph); 4.23 (s, 4 H, NCH_2N); 7.15–7.35 (m, 5 H, Ph); 7.42 (br.s, 2 H, NH).

2-Butylsulfonylimino-5-(4-chlorophenyl)hexahydro-1,3,5-triazine (3s). $^1\text{H NMR}$, δ : 0.8 (t, 3 H, Me, $J = 7.0$ Hz); 1.14–1.60 (m, 4 H, CH_2 of the chain); 2.75 (t, 2 H, CH_2 of the chain, $J = 7.6$ Hz); 4.77 (s, 4 H, NCH_2N); 7.18 and 7.35 (both d, 2 H each, Ar, $J = 8.5$ Hz); 7.65 (br.s, 2 H, NH).

Nitration of compound 3a. Compound **3a** (0.54 g, 2 mmol) was added portionwise to a mixture of concentrated H_2SO_4 (2.5 mL) and HNO_3 (d 1.47; 5 mL) cooled in an ice bath. The reaction mixture was stirred at 5 °C for 1 h and then poured onto crushed ice (20 g). The precipitate that formed was filtered off, washed several times with ice water, and dried in air. After crystallization from 50% EtOH, compound **3i** was obtained in a yield of 0.46 g (73.6%), m.p. 211–213 °C.

References

1. Eur. Pat EP 428.941; *Chem. Abstrs.*, 1991, **115**, 183374; Jpn. Pat. JP 10.45.755[98.145.755]; *Chem. Abstrs.*, 1998, **128**, 154104; Jpn. Pat. JP 08.245.322[96.245.322]; *Chem. Abstrs.*, 1997, **126**, 15863.
2. Jpn. Pat. 3573(61); *Chem. Abstrs.*, 1963, **58**, 10126.
3. P. R. Carter, D. H. Hey, and D. S. Morris, *J. Chem. Soc.*, 1932, 1353.
4. L. Kahovec, *J. Am. Chem. Soc.*, 1939, **33**, 8118.
5. J. Gramore, *J. Chem. Soc.*, 1932, 1353.
6. US Pat. 2.359.363; *Chem. Abstrs.*, 1945, **39**, 713.

Received November 2, 2000